By Medicine

Polypharmacy guidance: realistic prescribing
Scottish Government Effective Prescribing & Therapeutics Division
Polypharmacy icon of two pills

ACE inhibitor (Enalapril 2.5 - 20mg/day (uptitrated as tolerated) vs placebo, CKD

ACE inhibitor (Enalapril 2.5 - 20mg/day (uptitrated as tolerated) vs placebo, heart failure

ACE inhibitor (Enalapril 2.5 - 40mg/day (uptitrated as tolerated) vs placebo, asymptomatic heart failure

ACE inhibitor (Enalapril 2.5-40mg/day (uptitrated as tolerated) vs placebo, severe heart failure

ACE inhibitor (Ramipril 10mg/day) vs Placebo (High-risk of cardiovascular disease without LVSD or heart failure)

ACE inhibitor and Indapmide (perindopril 4mg/day and Idapamide 2.5mg/day) vs placebo

Alendronate 10mg tablets vs placebo

Alendronate vs placebo

Angiotensin II receptor antagonist (Telmistartan 80mg/day) vs placebo

Angiotensin II receptor blocker (Candesartan 4-32mg/day)

Antiplatelet, placebo or no treatment

Apixaban 5mg twice daily vs Warfarin - major bleeding

Apixaban 5mg twice daily vs Warfarin - stroke or systemic embolism

Aspirin & Dipyrdamole vs aspirin

Aspirin & Dipyridamole vs placebo

Aspirin or other antiplatelet vs placebo or no treatment

Aspirin vs placebo or no treatment

Betablocker (Bisoprolol titrated to target dose of 10mg/day) vs placebo

Betablocker (Carvedilol titrated to target dose of 25mg twice daily) vs placebo

Betablocker (Metoprolol modified release titrated to a target dose of 200mg /day) vs placebo

Betablocker (Nebivolol titrated to a target dose of 10mg/day) vs placebo

BP control (<140/90mmhg) patients with hypertension and age >80yrs

BP control (<140/90mmhg) patients with hypertension and >60 years

BP control (<140/90mmhg) patients with hypertension high risk and >60 years

BP control (<140/90mmhg) patients with hypertension high risk and greater than 80 years.

Dabigatran 110mg or 150mg twice daily vs Warfarin- major bleeding

Dabigatran 110mg or 150mg twice daily vs Warfarin - stoke or systemic embolism

Direct Acting Oral Anticoagulants (DOACs)

Edoxaban mg or 60mg daily vs Warfarin - stroke or systemic embolism

Edoxaban mg or 60mg daily vs Warfarin - major bleeding

Intensive control of glucose vs Hypoglycaemia agents chosen by the treating physician

Intensive sulphonylurea with insulin to achieve fasting plasma glucose less than 6.0mmol/

Metformin - achieve fasting blood glucose <6.0mmol/l vs diet alone - achieve fasting blood glucose, 15mmol/l

Rivaroxaban 20mg daily vs Warfarin - major bleeding

Rivaroxaban 20mg daily vs Warfarin - stoke or systemic embolism

Spironolactone 25mg daily vs placebo

Statin vs placebo, serious vascular events

Statin vs placebo, stroke

Thienopyridine derivative (Ticlopidine or Clopidogrel) vs Aspirin, stroke (all types)

Thienopyridine derivative (Ticlopidine or Clopidogrel) vs Aspirin, stroke, MI or vascular death

Warfarin (target INR 2-3) vs Aspirin 75mg daily